Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective

Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to poorly understood disease etiology, unpredictable disease progression, highly heterogeneous patient populations, and a lack of robust pharmacodynamic biomarkers. Moreover, because lung biopsy is invasive and dangero...

Descripción completa

Detalles Bibliográficos
Autores principales: Mai, Tu H., Han, Lyrialle W., Hsu, Joy C., Kamath, Nikhil, Pan, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333628/
https://www.ncbi.nlm.nih.gov/pubmed/37392011
http://dx.doi.org/10.1177/17534666231181537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333628/
https://www.ncbi.nlm.nih.gov/pubmed/37392011
http://dx.doi.org/10.1177/17534666231181537

Ejemplares similares